Decatur Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Decatur Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-6,875	Closed	-$1.19M	–	108
2015 Q1	$1.19M	Buy	6,875 +3,750	+120%	+$679K	0.15%	87
2014 Q4	$578K	Sell	3,125 -14,050	-82%	-$2.6M	0.08%	93
2014 Q3	$2.85M	Sell	17,175 -3,550	-17%	-$583K	0.48%	61
2014 Q2	$3.24M	Buy	+20,725	New	+$3.27M	0.61%	69

Other funds holding ALXN

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Decatur Capital Management's ALXN Position: Q2 2015 in Review

Decatur Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q2 2015, closing a stake of 6,875 shares — an estimated $1.19M sold.

Decatur Capital Management first reported a position in ALXN in Q2 2014 and held it in 4 quarters. The position peaked at $3.24M in Q2 2014. 548 funds tracked by Wall St. Rank hold ALXN as of Q2 2015.

Decatur Capital Management reported no remaining Alexion Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
Decatur Capital Management sold 6,875 Alexion Pharmaceuticals shares in Q2 2015, an estimated $1.19M.
Decatur Capital Management first reported a position in Alexion Pharmaceuticals in Q2 2014 and held it in 4 quarters.
Decatur Capital Management's Alexion Pharmaceuticals position peaked at $3.24M in Q2 2014.
548 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2015.

Based on Decatur Capital Management's 13F filing for Q2 2015, filed 10 Jul 2015.